NSF Regenerative Medicine Engine in North Carolina

Region of service

A national center for regenerative medicine commercialization

The Regenmed Engine builds on decades of foundational work by the Regenerative Medicine Development Organization and the Wake Forest Institute for Regenerative Medicine. These organizations have established the field's potential to become a major economic driver for the region and the nation.

Today, more than 250 regenerative medicine startups, industry organizations, nonprofits, academic and government partners collaborate across the state and the nation, creating an environment that draws global innovators and investors.

Addressing challenges in a key U.S. sector

The development of lifesaving and life-prolonging regenerative medicines is constrained by multiple factors. Today, only an estimated 10% of U.S.-produced technologies at the level of the cell or individual gene reach the market. This bottleneck is created by regulatory complexity, workforce shortages, limited manufacturing capacity, inadequate supply chains and constrained access to capital.

The Regenerative Medicine Engine directly addresses these barriers through:

• Cross-sector collaboration that reduces fragmentation and accelerates technology maturation.
• Regulatory navigation support that shortens time-to-approval.
• Specialized infrastructure supporting prototype development and manufacturing to increase commercialization speed and success.
• Workforce development that expands the talent pipeline for advanced biomanufacturing, executive leadership and advanced technology research and development staffing.

These capabilities emphasize commercialization pathways, domestic production and reducing structural barriers for emerging industries.

Services that accelerate time-to-market

The regenerative medicine test bed: De-risking early-stage development

The test bed provides subsidized access to state-of-the-art biomanufacturing equipment, enabling regenerative medicine-focused companies and research teams to prototype, validate and iterate without significant expense. This approach allows startups and established companies to de-risk their pilot research and prototypes in development.

The regenerative medicine regulatory navigator: Reducing approval timelines

The regulatory navigator offers real-world, actionable guidance that helps companies avoid costly delays and navigate complex regulatory pathways, directly supporting efficient, evidence-based regulatory processes.

Product trials catalyst: Accelerating clinical validation

With access to 67 hospitals, 1,000 outpatient facilities and 6 million individuals, the Regenmed Engine provides one of the nation's most robust product-testing networks. Streamlined support for procedures and contracting further reduce trial startup times and development success.

Regenerative medicine innovation accelerator and launch capacity: Lowering barriers to commercial entry

A variety of affordable real estate options exist to support Regenmed Engine companies. Options range from shared spaces to dedicated lab and office suites with varying footprints in planned multi-tenant manufacturing facilities and built-to-suit. Market assessment tools and business strategy support to help scale efficiently and sustainably are also available to accelerate translation and commercialization.

Workforce development: Talent and regional growth

The Regenmed Engine's workforce programs directly support skills-based hiring, access to high-wage jobs and regional workforce mobility.

Key initiatives include:

• Industry-training partnerships to design job-ready workforce programs.
• Hands-on technical training at community colleges, including micro-certifications in 3D bioprinting and advanced analytics.
• Access to industry-grade equipment for real-world experience.
• Statewide scaling through virtual and technology-enabled learning platforms.

These programs expand the talent pipeline for advanced biomanufacturing, one of the fastest-growing sectors in the U.S. economy.

Examples of recent impacts

Strong economic returns and commercial momentum

In its first two years, the Regenmed Engine generated approximately $300 million in investment capital and worked with more than 200 companies to advance breakthrough technologies.

Key metrics of economic growth:

• More than 40 regenerative medicine companies relocated to North Carolina.
• 101 new companies accessed Regenmed Engine services in 2025.
• More than 720 jobs created, many in high-wage technical fields.
• More than 1,500 individuals trained in regenerative medicine skills.

These outcomes demonstrate a strong return on federal investment and a compelling value proposition for private capital seeking high-growth opportunities in a strategically important sector.